Viking Therapeutics, Inc. NCM · VKTX
Price alert —
Sign in to get a one-time email the moment VKTX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · VKTX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.2B | $-0.2B | $-0.1B | — | — |
| 2025-12-31 | — | $-0.2B | $-0.2B | $-0.1B | — | — |
| 2025-09-30 | — | $-0.1B | $-0.1B | $-0.1B | — | — |
| 2025-06-30 | — | $-0.1B | $-0.1B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.1B | $-0.1B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare VKTX vs peers
Line VKTX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with VKTX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-29 | -1.37 | -0.91 | -50.5% | -0.5% |
| 2026-02-11 | -1.38 | -0.90 | -53.1% | +6.8% |
| 2025-10-22 | -0.81 | -0.67 | -20.1% | +8.0% |
| 2025-07-23 | -0.58 | -0.44 | -31.6% | +0.3% |
| 2025-04-23 | -0.41 | -0.31 | -31.7% | -0.5% |
| 2025-02-05 | -0.32 | -0.27 | -19.7% | -6.1% |
| 2024-10-23 | -0.22 | -0.24 | +8.1% | +21.2% |
| 2024-07-24 | -0.20 | -0.27 | +25.0% | +28.3% |
| 2024-04-24 | -0.26 | -0.28 | +6.0% | +5.8% |
| 2024-02-07 | -0.25 | -0.25 | -1.8% | +18.0% |
| 2023-10-25 | -0.23 | -0.22 | -5.8% | -9.4% |
| 2023-07-26 | -0.19 | -0.20 | +3.4% | -4.0% |
| 2023-04-26 | -0.25 | -0.24 | -4.7% | +0.3% |
| 2023-02-08 | -0.26 | -0.23 | -11.4% | +11.7% |
| 2022-10-26 | -0.21 | -0.23 | +9.1% | -2.9% |
| 2022-07-27 | -0.23 | -0.21 | -9.5% | +0.3% |
| 2022-04-27 | -0.21 | -0.19 | -11.8% | +10.0% |
| 2022-02-09 | -0.16 | -0.19 | +14.8% | +8.6% |
| 2021-11-03 | -0.17 | -0.21 | +18.7% | +2.1% |
| 2021-07-28 | -0.20 | -0.20 | -1.9% | +3.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| VKTX ★ | $4B | — | -8.1 | — | — | 8.6 | — | — | — | -4.12% |
| LLY | — | 41.8 | 26.3 | — | 30.1 | — | 82.8% | 55.5% | 169.9% | — |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | — | 36.0 | 13.2 | — | 12.1 | 6.9 | 76.7% | 4.9% | — | — |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | — | 19.1 | 8.8 | — | 7.6 | — | 74.8% | 5.4% | -10.1% | — |
| TMO | — | 29.2 | 19.5 | — | 21.1 | — | 40.9% | 6.2% | 11.3% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 34.87%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 6,880,290 | 5.93% |
| FMR, LLC | 6,024,753 | 5.19% |
| Vanguard Capital Management LLC | 5,012,502 | 4.32% |
| Vanguard Portfolio Management LLC | 4,464,298 | 3.85% |
| Two Sigma Investments, LP | 4,432,142 | 3.82% |
| State Street Corporation | 4,395,557 | 3.79% |
| Morgan Stanley | 3,013,928 | 2.60% |
| Raymond James Financial, Inc. | 2,075,403 | 1.79% |
| Geode Capital Management, LLC | 2,082,067 | 1.79% |
| American Century Companies Inc | 2,078,577 | 1.79% |
Insider activity · 90d
1 buys / 0 sells · ratio 1.0 · Finnhub
- Chen Hubert C BUY 190,000
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-03 | 4 | view · |
| 8-K | 2026-05-26 | 8-K | view · |
| 10-Q | 2026-04-30 | 10-Q | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| DEF 14A | 2026-04-01 | DEF 14A | view · |
| 4 | 2026-03-10 | 4 | view · |
| 10-K | 2026-02-11 | 10-K | view · |
| 8-K | 2026-02-11 | 8-K | view · |
| 4 | 2026-01-26 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2026-01-05 | 4 | view · |
| 4 | 2025-10-28 | 4 | view · |
| 4 | 2025-10-28 | 4 | view · |
| 4 | 2025-10-28 | 4 | view · |
| 4 | 2025-10-28 | 4 | view · |
| 10-Q | 2025-10-23 | 10-Q | view · |
| 8-K | 2025-10-22 | 8-K | view · |
| 8-K | 2025-08-19 | 8-K | view · |
| 10-Q | 2025-07-23 | 10-Q | view · |
| 8-K | 2025-07-23 | 8-K | view · |
| 4 | 2025-07-03 | 4 | view · |
| 4 | 2025-07-03 | 4 | view · |
| 4 | 2025-07-03 | 4 | view · |
| 8-K | 2025-05-27 | 8-K | view · |
| 10-Q | 2025-04-24 | 10-Q | view · |
| 8-K | 2025-04-23 | 8-K | view · |
| 8-K | 2025-04-23 | 8-K | view · |
| 4 | 2025-04-14 | 4 | view · |
| DEF 14A | 2025-04-08 | DEF 14A | view · |
| 4 | 2025-04-02 | 4 | view · |
| 8-K | 2025-03-11 | 8-K | view · |
| 10-K | 2025-02-26 | 10-K | view · |
| 8-K | 2025-02-05 | 8-K | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2025-01-06 | 4 | view · |
| 4 | 2024-11-08 | 4 | view · |
| 8-K | 2024-11-04 | 8-K | view · |
| 4 | 2024-10-28 | 4 | view · |
| 4 | 2024-10-25 | 4 | view · |
| 4 | 2024-10-25 | 4 | view · |
| 10-Q | 2024-10-23 | 10-Q | view · |
| 8-K | 2024-10-23 | 8-K | view · |
| 4 | 2024-09-20 | 4 | view · |
| 4 | 2024-09-20 | 4 | view · |
| 4 | 2024-08-22 | 4 | view · |
| 4 | 2024-08-22 | 4 | view · |
| 4 | 2024-08-19 | 4 | view · |
| 4 | 2024-08-19 | 4 | view · |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Options picks · VKTX
ITM + OTM ideas from the latest scanLoading…
Congress trades · VKTX
STOCK Act disclosuresLoading…
SEC filings & insiders · VKTX
EDGAR · liveLoading…
Holders · VKTX
Institutions & insider activityLoading…